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Angiogenesis Overview
Tumor growth is angiogenesis dependent
Angiogenesis is defined as the formation of new blood
vessels by proliferation of new capillaries from existing
microvessels. This process is distinct from vasculogen-
esis, which is defined as the formation of blood vessels
de novo from angioblasts [1,2]. Angiogenesis involves
degradation of the basement membrane surrounding
an existing capillary or venule, migration of endothelial
cells through the basement membrane to create a sprout,
proliferation of endothelial cells, formation of a lumen
within the new sprout and joining of two sprouts to
form a functional capillary loop, and vessel maturation
[3,4]. The idea that tumor growth is dependent on
angiogenesis was first proposed in 1971, allowing anti-
angiogenic therapy to be used to treat cancer [5]. The
development of a solid tumor progresses from a pre-
vascular phase to a vascular phase. The prevascular
tumor does not induce angiogenesis, is limited in
size, and rarely metastasizes. The vascularized tumor
induces host microvessels to undergo angiogenesis.
One genetic proof that tumor growth is angiogenesis
dependent is the induction of tumor angiogenesis by
ras oncogene [6]. Ras induces the sequential activation
of myc via a mechanism that enables it to repress the
expression of endogenous angiogenesis inhibitors,
e.g. thrombospondin-1 (TSP1) [7], and to activate
angiogenesis activators, e.g. vascular endothelial
growth factor (VEGF) [8]. Thus, blocking angiogenesis
can result in tumor dormancy and tumors that cannot
expand beyond a microscopic size [9]. Within dormant
tumors, proliferating tumor cells are balanced by
apoptotic tumor cells and few, if any, microvessels [10].
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Angiogenesis activators are produced by tumor cells
while inhibitors are endogenous
In the early 1980s, it became clear that tumor cells can
produce specific angiogenesis activators that stimulate
the proliferation of capillary endothelial cells [11]. The
growth of the tumor vasculature is no longer regarded
as an inflammatory reaction. Angiogenesis activators
are stored in the extracellular matrix (ECM) in “stand-
by mode” before they become activated by specific en-
zymes when angiogenesis is required, physiologically or
pathologically [9]. Angiogenesis inhibitors can be ex-
pressed by tumor cells or by normal host cells and are
endogenous molecular defense barriers in pathologic
hotspots of angiogenesis [9]. They are formed from
cryptic fragments of matrix protein, e.g. angiostatin
from plasminogen [12], endostatin from a fragment of
collagen XVIII [13], and tumstatin from collagen IV
[14]. The existence of naturally occurring angiogenesis
inhibitors, which a tumor must overcome to induce
angiogenesis, forms the basis of the concept of the
“angiogenic switch” [2,15].
Angiogenic switch depends on the balance of
angiogenesis activators and inhibitors
Bouck proposed that the onset of angiogenesis is the
result of a shift in the balance of angiogenesis activators
and inhibitors, which is controlled by oncogenes and
tumor suppressor genes [15]. The balance of activators
and inhibitors governs the angiogenic switch [2], which
is characterized by downregulation of angiogenesis
inhibitors or upregulation of angiogenesis activators,
or both. When inhibitors exceed activators, the switch
is “off”. When activators exceed inhibitors, the switch
is “on” [2]. Change in the balance of activators and
inhibitors activates the angiogenic switch, before
stabilizer molecules activate the maturation of nascent
blood vessels [3]. This change takes place within the
tumor cell itself and between the tumor cell’s angiogenic
proteins and the host’s anti-angiogenic proteins [2].
For a tumor to switch to the angiogenic phenotype, it
must overcome natural angiogenesis inhibitors in the
host’s circulation, the ECM or tumor cells. Rastinejad
et al demonstrated that tumor cells did not become
angiogenic until they had significantly reduced their
own production of TSP1 [16]. In certain tumors, the
angiogenic switch also involves downregulation of
endogenous angiogenesis inhibitors, in addition to
increased expression of angiogenesis activators. For
example, ras transfection decreases expression of TSP1
and increases VEGF expression [17].
Angiogenic process relies on complex tumor–host
interaction
The mechanisms of angiogenesis involve angiogenic
activity arising from at least two sources: tumor cells
that mediate the release of angiogenesis activators and
host cells (e.g. macrophages) recruited by the tumor
from the surrounding host ECM [6]. During angio-
genesis, there is a complex interaction among cell com-
ponents such as tumor, stromal, endothelial, and in-
flammatory cells, growth factors, and the ECM, which
are regulated by angiogenesis activators and inhibi-
tors [18].
Endothelial cells control the size of both normal tissue
and tumor
Tissue mass, whether it is neoplastic or normal, may be
regulated by microvascular endothelial cells [9]. Both
tumors and organs may limit their own growth by
increasing the production of angiogenesis inhibitors
with size, until a critical size is reached where further
growth is actively self-inhibited [19]. Tumor mass, as
well as normal organ size, is under the tight control of
the microvascular endothelium [20]. If normal cells are
similarly dependent on endothelium-derived paracrine
factors, the ratio of endothelial cells to normal pa-
renchymal cells is likely to be lower than for tumor cells.
Nevertheless, the regulation of tissue mass or organ
size by vascular endothelial cells may be based on
mechanisms that also operate in tumors [21]. Cancer
growth requires the proliferation of endothelial cells
in addition to malignant cells [22]. Without the prolif-
eration of endothelial cells, a tumor cannot grow beyond
the size of a colony. Folkman proposed the “two com-
partment model” to explain the interaction of endothelial
cells and tumor cells, which constitute two important
compartments of a tumor. Within a tumor, these two
cell compartments can stimulate each other’s growth
via a perfusion or paracrine effect [22]. Coordinated
tumor/vascular growth exploits an ultimate limitation
to tumor size under angiogenic control, where opposing
angiogenic stimuli come into dynamic balance [23].
During tumor angiogenesis, there is continued re-
cruitment of endothelial cells and continued expansion
of the tumor mass. Ultimately, each newly recruited
endothelial cell can support a large population of tumor
cells. This leverage may be exploited to cancer therapeutic
advantage [19]. Administration of an angiogenesis inhi-
bitor, which is not directly cytotoxic to tumor cells, can
increase tumor cell apoptosis and inhibit tumor growth
by inhibiting endothelial proliferation and migration, or
by inducing apoptosis in endothelial cells [24]. By ad-
ministering angiogenesis inhibitors to shift the stimu-
latory climate in the tumor back to inhibition, recruited
endothelial cells are removed, followed by loss of the
relatively abundant supported tumor cells [19,23].
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Angiogenic Switch in Cervical Neoplasm
Angiogenesis plays an important role in cervical
carcinogenesis
Cervical cancer is the second most common malignancy
among women worldwide, with nearly 80% of cases
arising in less developed countries. There are approx-
imately 500,000 diagnoses of cervical cancer per year,
leading to 200,000 deaths each year [25]. Cervical
cancer develops usually by a sequence of gradual,
stepwise events starting with low-grade squamous
intraepithelial lesion (LSIL) and progressing through
high-grade squamous intraepithelial lesion (HSIL) to
invasive cancer [26]. Tumor development and metastasis
is a complex process that includes transformation, pro-
liferation, neovascularization, and metastatic spread.
Angiogenesis is now regarded as one of the most
important events occurring in the neoplastic process,
and its role in cervical neoplasm is evident [27,28].
Hockel et al reported an association between tumor
hypoxia and progression of cervical cancer, and this
would seem to correlate with the angiogenic potential
of the tumor [29]. However, trying to connect this
finding with actual vessel counts or angiogenic factors
has proven difficult. Two commonly used tumor
vascularity measurements are microvessel density
(MVD), the hotspot method that provides a histologic
assessment of tumor angiogenesis, and intercapillary
distance (ICD), which is thought to reflect tumor
oxygenation [30]. Accumulating evidence has shown
that angiogenesis is related to cervical neoplasm in
histologic parameters, prognosis, survival [31], and
therapeutic efficacy [32,33].
Timing of angiogenic switch in cervical carcinogenesis
The timing of the angiogenic switch during cervical
carcinogenesis remains controversial. There is debate
about the ability of cervical intraepithelial neoplasm
(CIN) to induce angiogenesis [34–36]. Smith-McCune
and Weidner found a significant increase in MVD in CIN
III lesions compared with underlying low-grade lesions
such as condyloma and CIN I [34]. Sotiropoulou et al
reported that there was also a significant difference in
the number of vessels between carcinoma in situ (CIS)
and controls, but no significant correlation was found
in relation to depth of invasion and histologic grade of
the microinvasive carcinoma [28]. On the contrary,
Abulafia et al showed that microinvasive squamous cell
carcinoma (SCC), but not CIS, is angiogenic [36]. In
order to eliminate the inborn heterogeneity in angio-
genesis, we examined surgical specimens with lesions of
different severity within the same histologic slide, so
that each lesion could be used as an internal control for
the others [37]. Our data showed that the angiogenic
switch occurred during the transition from low-grade
CIN to high-grade CIN, and that neovascularization
was largely confined to a narrow zone immediately
underneath the dysplastic epithelium [37]. This is in
concordance with the results of Smith-McCune and
Weidner [34] and Sotiropoulou et al [28]. Altogether,
it seems that the onset of angiogenesis in cervical cancer
is an early event, usually at a pre-invasive stage, which
supports that cervical carcinogenesis is angiogenesis
dependent [9,28].
MVD and Other Modalities in Evaluation of
Angiogenic Status
Usefulness of MVD
One often-quantified aspect of tumor vasculature is
MVD. However, whether MVD measurement reflects
every aspect of angiogenesis remains controversial.
MVD measurement within isolated regions of high
vessel concentration (i.e. hotspots) is a significant and
independent prognostic indicator in early-stage breast
carcinoma [38]. MVD is a measure of the number of
vessels per high-power field and reflects the ICD. ICDs
are determined at the local level by the net balance
between angiogenesis activators and inhibitors in each
microenvironment; they do not reflect the angiogenic
activity or angiogenic dependence of a tumor [39].
Thus, MVD may be a useful prognostic indicator but it
may not be useful in monitoring anti-angiogenic
treatment efficacy [39]. Though both vascularity
measurements, ICD and MVD, provide independent
prognostic information in multivariate analysis in cervical
neoplasm, there is only significant correlation between
tumor hypoxia and ICD, not MVD [40].
MVD used as prognostic indicator in cervical
neoplasm
MVD serves as a prognostic indicator in cervical SCCs
[27,35,41]. Together with depth of invasion, regional
lymph node status, and vascular invasion, it is a strong
independent prognostic indicator for overall survival in
patients with clinical stage IB cervical carcinoma [42].
MVD may play a role in predicting recurrence and sur-
vival in patients with stage II SCC [31]. Nevertheless,
two reports independently show that high MVD predicts
improved survival in cervical cancer patients treated
with radiotherapy [32] or intra-arterial chemotherapy
[33]. Vascular densities were significantly higher in the
effective group than the non-effective group. Rutgers et
al also reported that increased angiogenesis in SCC of
the cervix is not associated with a worsened prognosis
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[43]. Another study showed that MVD was not a
significant prognostic factor, although it might be
associated with the presence of lymph node metastases
and vascular space invasion by tumor cells [44].
It is possible that the discrepancies in results from
MVD assays are due to the methodology used. For
example, different types of antibody, as well as whether
MVD is assessed at the periphery or center of the tumor,
can influence its value as a prognostic indicator. Vieira
et al compared the performance of three different
monoclonal antibodies, anti-CD31, anti-CD34, and
BNH9, in the quantification of angiogenesis in cervical
cancer [45]. MVD estimated using anti-CD34 and BNH9
was significantly higher than that estimated using anti-
CD31. Furthermore, the agreement between anti-CD34
and BNH9 to quantify MVD was higher than that
between anti-CD31 and other antibodies.
MVD may not be an indicator of anti-angiogenic
treatment efficacy
It is a common misconception that anti-angiogenic
treatment can only be used in cancers with high MVD.
However, MVD does not reflect the angiogenic activity
or angiogenic dependence of a tumor [39]. Since virtually
all tumors are angiogenesis dependent, low MVD within
a tumor is not a sufficient criterion to exclude patients
from treatment with angiogenesis inhibitors [19]. Also,
MVD is not predictive of tumor response under anti-
angiogenic treatment and, therefore, is not useful for
stratifying patients for clinical trials [39]. There is a
considerable degree of heterogeneity in the intensity of
angiogenesis within each tumor. In many situations, the
MVD in a tumor is lower than that in its corresponding
normal tissue [46]. Also, rapid tumor growth does not
imply high MVD, because tumor cells can remain viable
at lower oxygen concentrations. In other words, they
can exist at greater distances from the vasculature than
can their normal counterparts.
Individual tumors can make a wide variety of an-
giogenesis activators, and the relative expressions of
these factors can change over time. The net angiogenic
influence of the tumor microenvironment should be
thought of as the sum of the angiogenesis activators and
inhibitors that arise from both tumor cells [23] and host
tissues [47]. Tumor MVD may not vary in accordance
with the tissue or blood levels of any single angiogenesis
activator [39]. Anti-angiogenic therapy has an ultimate
limitation to tumor size under angiogenic control, where
opposing angiogenic stimuli come into dynamic balance
[23]. All tumor vessels are not equal in their ability to
provide oxygen and nutrients to the tumor cells they
support. Some can be ineffective. Thus, inhibition of
ineffective vessels has little effect on the reduction of
tumor growth [39]. The lack of a parallel relationship
between tumor size and MVD points to the error in
interpreting the lack of a decrease in MVD during ther-
apy as a failure to inhibit vascularization. Thus, the ef-
ficacy of anti-angiogenic agents cannot be simply visual-
ized using alterations in MVD during treatment [39].
Other models for studying angiogenesis
Though MVD offers a convenient way to evaluate
angiogenesis, it has limitations. Hypoxia may not be
morphologically detectable and is more likely to be
detected by functional imaging than by histologic tissue
assessment [48]. Cheng et al developed a novel method
to evaluate in vivo angiogenesis in patients with cervical
carcinoma [49]. Using color Doppler ultrasound and
quantitative image processing, they found that the
intratumoral vascularity index (VI), but not resistance
index, showed good correlation with tumor stage, tumor
size, depth of stromal invasion, lymphovascular emboli,
and pelvic lymph node metastases. VI is well correlated
with the conventional indicator of tumor angiogenic
activity, MVD. The combined use of three-dimensional
(3D) imaging and power Doppler provides the possibil-
ity of assessing cervical cancer volume and quantifying
the power Doppler signal in the whole target organ,
in contrast to two-dimensional (2D) ultrasound, where
information on vascularization and blood flow is re-
stricted to one subjectively chosen 2D plane. We have
demonstrated that 3D power Doppler ultrasound
accurately measures cervical cancer volume and provides
a global assessment of vascular heterogeneity [50].
Therefore, it can be used to monitor response to, and
vascular changes in tumors after anti-angiogenesis
therapy. Tumor vascularity and oxygenation have long
been implicated as important determinants of radia-
tion therapy [48], and tumor oxygenation levels can
be measured using a sterile polarographic needle elec-
trode [51]. Alternatively, dynamic contrast-enhanced
magnetic resonance imaging (MRI) is used to assess
tissue microcirculation. Tumor perfusion imaging is
noninvasive, potentially easy to implement clinically,
and reproducible for therapeutic monitoring [52,53].
Dynamic contrast MRI is based on the combination of
rapid dynamic MRI techniques and bolus injection of
gadolinium (Gd) contrast agent. In the first-pass (bolus
injection) method, contrast enhancement patterns
are used to assess tissue microcirculation [52]. The
equilibrium method is based on the tracer-kinetic model
to measure tissue perfusion [53]. There is reportedly a
significant correlation between tumor oxygenation
measured on a pO2 histograph and maximal tumor
enhancement in dynamic contrast-enhanced MRI. How-
ever, intratumor MVD and MRI parameters are not
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significantly correlated [51]. Results from Mayr et al
further suggest that MR microcirculation parameters
do not always correlate with histomorphometric pa-
rameters, while there is evidence that MR parameters
predict treatment outcome [48]. It can be interpreted
that MR microcirculation assessment may reflect the
“dynamic” angiogenic and metabolic status of a tumor,
rather than the “static” single time point provided by
histomorphologic parameters.
Various in vivo and in vitro models have been developed
to test the effects of angiogenic agonists or antagonists.
In developing an animal model for angiogenesis study,
Guedez et al described the directed in vivo angiogenesis
assay (DIVAA) to overcome difficulties in quantifying
the angiogenic response [54]. The assay consists of
subcutaneous implantation of semi-closed silicone
cylinders (angio-reactors) into nude mice, and the results
seem reproducible and quantitative in dose–response
analysis; DIVAA can identify the effective doses of
angiogenesis-modulating factors in vivo. Alternatively,
the Matrigel-perfusion assay is widely used to measure
angiogenesis [55]. Matrigel, an ECM gel-like plug,
containing angiogenic factors and/or an experimental
inhibitor is implanted into the skin of mice. The new
blood vessels that grow into the plug can be quantified
by measuring perfusion by hemoglobin or large
fluorescently tagged molecules (such as intravenously
administered dextran) into the plugs. Subsequently,
Guidolin et al described an automatic image analysis
method to evaluate angiostatic activity using the in vitro
Matrigel assay [56]. This method allows several
parameters to be established, such as dimensional
(percentage area covered by endothelial cells and total
length of the cellular network per field), topologic
(number of meshes and number of branching points
per field), and fractal (fractal dimension, lacunarity)
parameters of the capillary-like network. The results
indicate that both topologic and fractal parameters
allow characterization of the spatial texture generated
by endothelial cells during in vitro angiogenesis, although
topographic parameters exhibit a wider dynamic range
than fractal ones [56]. The analysis can be implemented
in a computer program to facilitate calculation.
How Does the Angiogenesis Inhibitor
TSP1 Regulate Angiogenesis in Cervical
Neoplasm?
Role of angiogenesis activators in cervical neoplasm
VEGF is a disulfide-bonded glycoprotein whose
transcription and expression are upregulated with
hypoxia and appear to play an important role in the
development and growth of tumors [57]. The tumor
microvasculature, accompanied by overexpression of
VEGF, is progressively upregulated during cervical
carcinogenesis. VEGF is significantly increased in HSIL
compared with LSIL and benign epithelium [58]. Dobbs
et al found progressive increases in MVD and VEGF
expression from CIN I through CIN III to invasive SCC
[59]. There is a strong correlation between MVD and
VEGF expression, and both are associated with histologic
grade of CIN. The onset of angiogenesis is an early event
in premalignant changes in the cervix due, in part, to
enhanced expression of VEGF by the abnormal epi-
thelium. Cheng et al found that cytosolic VEGF might
be a biomarker for pelvic lymph node status in early
cervical carcinoma and an independent prognostic
indicator of overall survival [60]. On the contrary,
Raleigh et al found no relationship between hypoxia
and VEGF expression in cervical cancer [61]. In summary,
it appears that hypoxia is important in the response of
cervical tumors to treatment, but the actual angiogenic
factors that play a role in the development and pro-
gression of cervical tumors are not yet clear [62].
TSP1 may play a comparative role to VEGF
TSP1, a 450-kDa glycoprotein expressed in platelets
and ECM, was first discovered by Baenziger et al in 1971
as a large glycoprotein released from platelet alpha
granules upon activation [63]. The TSPs are a family of
extracellular proteins that participate in cell-to-cell and
cell-to-matrix communication. Five family members have
been identified [64]. TSP1 and TSP2 can inhibit angio-
genesis in response to many angiogenic cytokines and
growth factors such as basic fibroblast growth factor
(bFGF) and VEGF [65]. Evidence suggests that TSP1 is
involved in angiogenesis. However, the mechanisms by
which TSP1 regulates angiogenesis are not well known,
and the exact role of TSP1 in angiogenesis has been
controversial; both stimulatory [66] and inhibitory
effects [67] have been reported.
Upregulation of angiogenesis activators alone
may not be enough for the angiogenic switch; it is
accompanied by downregulation of some angiogenesis
inhibitors [68]. Rastinejad et al demonstrated that
tumor cells do not become angiogenic until they have
significantly reduced their production of TSP1 [16].
VEGF is significantly increased in HSIL compared with
LSIL and benign epithelium [58]. TSP1, as an endo-
genous angiogenesis inhibitor, may play a comparable
role to other angiogenesis activators such as VEGF in
angiogenesis balance during cervical carcinogenesis. In
the skin cancer model, downregulation of TSP1 and
upregulation of VEGF are coincident and are spatially
correlated throughout the consecutive stages of
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tumorigenesis [69]. Additionally, Kwak et al showed
higher VEGF and lower TSP1 expression in prostate
cancer than in non-cancerous tissue [70]. Genetic
evidence also implies that TSP1 and VEGF play a com-
parative role to each other; overexpression of VEGF and
downregulation of TSP1 can be triggered by the same
oncogene, ras, and the loss of function of the tumor
suppressor gene p53. Activating mutations in K-ras and
H-ras upregulate VEGF expression and downregulate
TSP1 expression [8,71]. Wild-type p53 normally sup-
presses tumor angiogenesis by upregulating TSP1 [72]
and suppressing transcription of VEGF [73]. TSP1 and
VEGF appear to be the constituents of a “switch” that
regulates, in concert, many components of the angio-
genic and differentiated phenotypes of endothelial cells.
TSP1 acts as an “angiogenic fence” during cervical
carcinogenesis
In bladder cancer, downregulation of TSP1 secretion is
a key event in the switch from an anti-angiogenic to an
angiogenic phenotype, while VEGF seems to play little
part [74]. Recent work has identified TSP1 as an en-
dogenous angiogenesis inhibitor that plays an impor-
tant role in the angiogenic switch in skin, prostate,
and bladder cancers [69,74,75]. Wu et al examined the
spatial and temporal expression of TSP1 in patients
with pre-invasive and invasive SCC of the uterine cervix
[37]. TSP1 decreased significantly during the transition
from LSIL to HSIL, with a concomitant increase in MVD.
TSP1 was mainly localized on basal cervical epithelial
cells, and arrayed like a barrier, and was therefore
proposed as the “TSP1 fence”. The temporal and spatial
concordance of TSP1 downregulation and the emer-
gence of angiogenesis, which occurs in the early phase
of cervical carcinogenesis, imply that the TSP1 fence
may act as an angiogenic barrier, inhibiting angio-
genesis. The disappearance of the angiogenic barrier
may induce a vigorous angiogenic response for tumor
growth and, perhaps, tumor metastasis [76].
The origin of TSP1 production is currently unknown,
with two origins, tumor cells themselves and host cells
(e.g. stromal, endothelial cells, etc), possibly responsible
[6]. Data suggest that basal epithelial cells contribute
to the production of TSP1 under physiologic conditions
but lose the ability to secrete TSP1 during the transition
from LSIL to HSIL [37]. Kodama et al showed that TSP1
mRNA expression is significantly lower in advanced-
stage cervical cancer and that its expression is of value
as a prognostic factor in cervical cancer [77]. The
inverse correlation between TSP expression and MVD
also indicates that decreased TSP expression may be
associated with an angiogenic phenotype in this class of
neoplasm.
Do TSP1 or other angiogenesis inhibitors play a
physiologic gatekeeper role in cancer prevention?
It has been suggested that TSP1 acts as an “angiogenic
fence” to inhibit angiogenesis during cervical carcino-
genesis [37]. The loss of the TSP1 barrier in early cervical
cancer lesions leads to a more aggressive and more
vascular cancer phenotype. In a related situation, ele-
vated levels of the angiogenesis inhibitor endostatin in
conjunction with elevated VEGF are associated with
either a more aggressive phenotype or with metastasis
or shortened survival in renal cell cancer, colon cancer,
and soft tissue sarcoma [78–80]. These observations
show that the angiogenesis inhibitors can be modulated
as a result of changes in the tumor environment or in
tumor disease burden [81,82]. Although circulating
angiogenesis activators such as bFGF, VEGF, and angio-
genin have been evaluated as diagnostic and/or prog-
nostic factors in cancer patients, little is known about
the clinical significance of angiogenesis inhibitors.
Neither the source of TSP1 nor its mechanism of protein
externalization has been clarified in detail [83].
The cause–effect relationship of TSP1 as a gatekeeper
during cervical carcinoma development has not been
clearly established. Although TSP1 levels decrease with
the increasing malignancy potential of lesions, these
determinations are only semi-quantitative and may be
influenced by the degree of antibody reactivity and
variability in the samples [84]. Meanwhile, the inverse
relationship between TSP1 staining and severity of tumor
lesions may be influenced directly or indirectly by other
processes, e.g. angiogenic factors. Similarly, a cause–
effect relationship has never been established between
increasing MVD and decreasing TSP1 level [84]. The
prevention of blood vessel development appears to be
the mechanism of action of many successful chemo-
preventive drugs of natural or synthetic origin, which is
termed “angioprevention”. The hypothesis that anti-
angiogenesis is the basis of tumor prevention also
suggests that many anti-angiogenic drugs could be
used for chemoprevention in higher-risk populations
or in early intervention. There is a growing body of
experimental evidence that anti-angiogenic strategies
will contribute to the future therapy of cancer [85].
Further work on the therapeutic implications of angio-
genesis inhibitors includes elucidation of the cause–
effect relationship between changes in these inhibitors
and tumor progression. Proof of such a relationship
would provide a rationale for the use of angiogenesis
inhibitors as preventive agents in patients at high risk for
developing cancer.
TSP1 may influence angiogenesis by changing the ECM
The disappearance of the “TSP1 fence” modulates the
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pericellular environment and potentially changes the
cell–matrix interactions associated with cell movement
and further progression. The basement membrane, a
specialized form of the ECM, is involved in the regulation
of tumor angiogenesis [86]. TSP1 does not appear to
contribute directly to the structural integrity of connective
tissue elements. Instead, it acts by modulating the
activity and bioavailability of protease and growth factors
and by interaction with cell-surface receptors [87,88].
Matrix metalloproteinases (MMPs) play an active role
in the neovascularization of tumors through their ability
to degrade the ECM [89,90]. Bergers et al showed that
the switch from vascular quiescence to angiogenesis
involves MMP9, which is upregulated in angiogenic
islets and tumors, rendering VEGF more available to its
receptors [91]. Notably, MMP9 is negatively modulated
by TSP1. Thus, TSP1 acts as a multifunctional modulator
of angiogenesis by modulating the activity and
bioavailability of MMP9 [66,92]. How TSP1 modulates
MMPs in cervical carcinogenesis deserves further study.
Anti-angiogenic Therapy Offers a Paradigm
Shift for Anticancer Therapy
Tumor vasculature as a therapeutic target
There are some limitations to conventional chemo-
therapy, e.g. tumor cells easily develop resistance to cy-
totoxic agents that cause DNA damage or disrupt DNA
replication, a phenomenon related to their genomic in-
stability after varying periods of sensitivity [93]. Con-
ventional chemotherapy is normally given on one or
more consecutive days, followed by 3- to 4-week periods
of rest, to allow recovery of normal proliferating cells,
mainly bone marrow progenitors. The applied clinical
strategy involves multidrug regimens designed to kill as
many tumor cells as possible by administering combined
cytotoxic agents at the maximum tolerated dose (MTD).
The goal is to obtain total eradication of cancer cells
[94]. However, most solid neoplasms are the result of
multiple genetic abnormalities and may contain heter-
ogeneous subpopulations of cells with different cell
kinetics and invasive and metastatic properties [95].
Increasingly, research highlights the importance of
tumor–host interactions and of the surrounding micro-
environment in tumor development, invasiveness,
metastasis, and responsiveness to therapy. There are
some advantages regarding the tumor vasculature as
a therapeutic target. It is composed of more genetically
stable cells than tumor cells and is less likely to acquire
chemoresistance. There are fewer systemic side-effects
and less toxicity with angiogenesis inhibitors than with
other cytostatic agents. They offer more feasibility of
long-term administration and can be combined with
other cytostatic and/or molecularly targeted therapy
[94]. Furthermore, the tumor endothelium is qualita-
tively distinct from normal endothelium at the mo-
lecular level, so it offers a specific and selective target
[96]. Systemic administration of inhibitors can easily
reach the target at the concentration of drug needed
[94]. The tumor endothelium may proliferate under the
stimulus of known growth factors, so therapeutic
neutralization of endothelial cell growth factors can
also be used as a therapeutic modality [97]. The pro-
liferation and migration of tumor endothelium can be
inhibited by naturally occurring angiogenesis inhibi-
tors, e.g. endostatin, angiostatin, TSP1, etc. [13,98].
Endothelial cells do not appear to acquire resistance to
some anti-angiogenic agents, which offers the possi-
bility of re-inducing a response after interruption of
therapy [99].
Low-dose “metronomic” chemotherapy is anti-
angiogenic
Surprisingly, cytotoxic chemotherapy has anti-
angiogenic effects, particularly when administered at
low and frequent doses. This scheduling is more effective
in targeting the tumor endothelium than large single
bolus doses followed by long rest periods [98]. Con-
ventional cytotoxic chemotherapeutic drugs were
designed to treat cancer by directly killing or inhibiting
the proliferation of rapidly dividing tumor cells. How-
ever, recent studies have highlighted the possibility
that cytotoxic agents might reasonably be considered to
have meaningful anti-angiogenic activity as a secondary
mechanism [100]. Browder et al developed an alter-
native anti-angiogenic schedule for administration of
cyclophosphamide that provided more sustained
apoptosis of endothelial cells within the vascular bed
of a tumor [98]. The use of chronically administered
chemotherapeutic agents in a frequent, even daily,
schedule with no prolonged drug-free breaks at low
doses significantly below the MTD is called “anti-
angiogenic” or “metronomic” chemotherapy [101].
Studies of the anti-angiogenic activity of metronomic
chemotherapy have been conducted in vivo in a mouse
corneal model [102], disc model [103], and chorio-
allantoic membrane model [103]. The sustained and
potent anti-angiogenic effects are based on targeting
the endothelial cells of newly growing tumor blood
vessels [97,98]. Activated, differentiated endothelial
cells, as well as circulating endothelial progenitor cells,
are sensitive to low-dose chemotherapy [104,105].
The potential advantages of metronomic chemo-
therapy include: significant delay in the onset of
mutation-dependent mechanisms of acquired drug
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resistance, because the target of the therapy is presumed
to be genetically stable, activated endothelial cells rather
than genetically unstable, highly mutable cancer cells
[106]; facilitation of the efficacy and durability of long-
term integration of chemotherapy drugs with targeted
anti-angiogenic agents [97]; reduction or loss of
traditional toxic side effects due to the high sensitivity
and selectivity [104,107]; and induction of an anti-
angiogenic effect by decreasing the mobilization and/or
viability of circulating bone marrow-derived endothelial
precursor cells [108].
TSP1 plays angio-inhibitory roles by direct targeting
or as a mediator of low-dose metronomic
chemotherapy
TSP1 has potent angio-inhibitory effects in epithelial
tumor development. Human SCC cell lines, stably trans-
fected to overexpress human TSP1, exhibit inhibited
tumor growth or completely abolished tumor formation
in xenotransplants [67]. In addition to the direct tar-
geting effects, Bocci et al reported that protracted ex-
posure of endothelial cells in vitro to low concentrations
of cytotoxic chemotherapeutic drugs caused marked
induction of gene and protein expression of TSP1 [106].
Increases in circulating TSP1 were also detected in the
plasma of human tumor-bearing severe combined
immunodeficient mice treated with metronomic low-
dose cyclophosphamide. The induced angiogenesis
inhibitor can cause further growth arrest or apoptosis of
endothelial cells. The induction of TSP1, as a second-
ary mediator of anti-angiogenic effects, in low-dose
metronomic chemotherapy regimens can explain the
“indirect” pathway to induce growth arrest or apoptosis
of endothelial cells [55]. In summary, TSP1 may exhibit
its anti-angiogenic effects in two ways: direct targeting
of the endothelium and as a mediator of metronomic
chemotherapy.
Paradigm shift from conventional dose-density
chemotherapy to metronomic scheduling
Significant anti-angiogenic and antitumor effects are
unlikely to be achieved in the clinical setting with a sin-
gle chemotherapeutic agent at metronomic doses.
Pioneering studies by Kakeji and Teicher showed po-
tentiality or synergism when angiogenesis inhibitors
were combined with standard schedules of certain
cytotoxic agents [109]. The efficacy of metronomic
chemotherapy can be significantly increased when ad-
ministered in combination with anti-angiogenic drugs,
such as antibodies against VEGF or VEGF receptor 2
[97]. Browder et al used cyclophosphamide and TNP-
470 to reveal the ability of cancer chemotherapy to
eradicate chemoresistant tumors [98]. The proposed
rationale for the beneficial effect of such combinations
was based on their ability to target both the parenchymal
and stromal components of neoplasia [110]. Tumor
endothelial targeting and tumor cell targeting should
not be thought of as mutually exclusive. Anti-angiogenic
therapy can be added to chemotherapy, radiotherapy,
immunotherapy, gene therapy, or any other traditional
cancer cell-directed modality [19].
A “new” paradigm for chemotherapeutic dosing is
theoretically based on targeting the vascular system of
the tumor rather than the tumor itself by using low-dose
continuous chemotherapy [111]. As angiogenesis
inhibitors become more widely used in anticancer
therapy, it will be important to reduce the harsh side-
effects and risk of drug resistance with conventional
chemotherapy [9]. The paradigm of anticancer
treatment may shift from cancer-centered to epigenic,
endothelium-centered therapy [19]. The focus is not on
the gene alterations within tumor cells, but on physiologic
constraints imposed on the overall tumor system [111].
Conventional anticancer therapy uses cytotoxic drugs
to kill tumor cells and to achieve the goal of cancer
eradication. Homogeneous groups of patients are
treated with the same chemotherapeutic schedule [94].
Individual tailored therapy uses metronomic therapy
and/or molecular target treatments (e.g. angiogenesis
inhibitors) to target the molecular abnormalities involved
in tumor and endothelial cells to achieve the goal of
cancer control in each patient [94]. The final goals of
anti-angiogenesis therapy are not to cure cancer, but to
make cancer more survivable and controllable, and
eventually to be converted to a chronic manageable
disease, like heart disease or diabetes, especially in
conjunction with radiation, chemotherapy, and other
treatments [112].
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